Literature DB >> 24619956

Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells.

Inga Koneczny1, Axel Schulenburg2, Xenia Hudec1, Martin Knöfler3, Klaus Holzmann1, Gary Piazza4, Robert Reynolds5, Peter Valent6, Brigitte Marian1.   

Abstract

Expansion of a stem-like subpopulation with increased growth and survival potential is thought to drive colorectal tumor growth and progression. We investigated a CD44-positive (CD44((+))) subpopulation with extended growth and survival capacity in the human colon adenoma cell line LT97. This subpopulation expressed elevated levels of fibroblast growth factor 18 (FGF18) and fibroblast growth factor receptor FGFR3-IIIc. Expression levels of the FGFR3-IIIb, which does not bind FGF18, were similar in CD44((+)) and CD44((-)). Addition of FGF18 to the medium or its overexpression from an adenoviral vector increased the colony formation capacity of CD44((+)) threefold, and stimulated phosphorylation of ERK and GSK3β in both total LT97 populations and CD44((+)) cells. FGFR3 signaling blockade by expression of a dominant-negative FGFR3-IIIc mutant led to inhibition of both colony formation and down-stream signaling in the CD44((+)) cells. CD44((-)) cells did not respond. Blockade of the wnt-pathway by a dominant-negative Tcf4-mutant inhibited FGFR3 activation in LT97 cells as well as in HT29 colorectal cancer cells. The chemical wnt-inhibitor sulindac sulfide amide inhibited expression of FGF18 and FGFR3-IIIc and led to inhibition of receptor activation to less than 30% of control treated cells, both in LT97 and HT29 cultures. Our results demonstrate that an FGF18/FGFR3-IIIc autocrine growth and survival loop is up-regulated in a wnt-dependent manner and drives tumor cell growth in a subpopulation of colon adenoma cells. This subpopulation can be regarded as a precursor of colon cancer development and can be targeted for CRC-prevention by blocking either wnt- or FGFR3-signaling.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD44; FGF; colon adenoma

Mesh:

Substances:

Year:  2014        PMID: 24619956      PMCID: PMC4162857          DOI: 10.1002/mc.22146

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  29 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.

Authors:  Nan Li; Yaguang Xi; Heather N Tinsley; Evrim Gurpinar; Bernard D Gary; Bing Zhu; Yonghe Li; Xi Chen; Adam B Keeton; Ashraf H Abadi; Mary P Moyer; William E Grizzle; Wen-Chi Chang; Margie L Clapper; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-06-26       Impact factor: 6.261

3.  Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells.

Authors:  Wolfgang Holnthoner; Manuela Pillinger; Marion Groger; Klaus Wolff; Anthony W Ashton; Chris Albanese; Peter Neumeister; Richard G Pestell; Peter Petzelbauer
Journal:  J Biol Chem       Date:  2002-09-15       Impact factor: 5.157

4.  Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.

Authors:  Pamela L Rice; Jennifer Kelloff; Holly Sullivan; Linda J Driggers; K Scott Beard; Scott Kuwada; Gary Piazza; Dennis J Ahnen
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

5.  Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex.

Authors:  Takashi Shimokawa; Yoichi Furukawa; Michihiro Sakai; Meihua Li; Nobutomo Miwa; Yu-Min Lin; Yusuke Nakamura
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.

Authors:  Evrim Gurpinar; William E Grizzle; John J Shacka; Burton J Mader; Nan Li; Nicholas A Piazza; Suzanne Russo; Adam B Keeton; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

7.  Fibroblast growth factor receptor-3 is expressed in undifferentiated intestinal epithelial cells during murine crypt morphogenesis.

Authors:  Alda Vidrich; Jenny M Buzan; Chibuzo Ilo; Leigh Bradley; Kirstin Skaar; Steven M Cohn
Journal:  Dev Dyn       Date:  2004-05       Impact factor: 3.780

8.  Fibroblast growth factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal development.

Authors:  Alda Vidrich; Jenny M Buzan; Brooks Brodrick; Chibuzo Ilo; Leigh Bradley; Kirstin Skaar Fendig; Thomas Sturgill; Steven M Cohn
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-30       Impact factor: 4.052

9.  FGF-18 is a neuron-derived glial cell growth factor expressed in the rat brain during early postnatal development.

Authors:  Masamitsu Hoshikawa; Akiko Yonamine; Morichika Konishi; Nobuyuki Itoh
Journal:  Brain Res Mol Brain Res       Date:  2002-09-30

10.  Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.

Authors:  E M J Boon; J J Keller; T A M Wormhoudt; F M Giardiello; G J A Offerhaus; R van der Neut; S T Pals
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  9 in total

Review 1.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

2.  Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

Authors:  Rohit Mathur; Lalit Sehgal; Frank K Braun; Zuzana Berkova; Jorge Romaguerra; Michael Wang; M Alma Rodriguez; Luis Fayad; Sattva S Neelapu; Felipe Samaniego
Journal:  J Hematol Oncol       Date:  2015-06-06       Impact factor: 17.388

3.  Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.

Authors:  Zeynep N Erdem; Stefanie Schwarz; Daniel Drev; Christine Heinzle; Andrea Reti; Petra Heffeter; Xenia Hudec; Klaus Holzmann; Bettina Grasl-Kraupp; Walter Berger; Michael Grusch; Brigitte Marian
Journal:  Transl Oncol       Date:  2017-03-22       Impact factor: 4.243

Review 4.  Wnt signaling in orofacial clefts: crosstalk, pathogenesis and models.

Authors:  Kurt Reynolds; Priyanka Kumari; Lessly Sepulveda Rincon; Ran Gu; Yu Ji; Santosh Kumar; Chengji J Zhou
Journal:  Dis Model Mech       Date:  2019-02-04       Impact factor: 5.758

5.  Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.

Authors:  Leisl M Packer; Samantha J Stehbens; Vanessa F Bonazzi; Jennifer H Gunter; Robert J Ju; Micheal Ward; Michael G Gartside; Sara A Byron; Pamela M Pollock
Journal:  Mol Oncol       Date:  2019-01-18       Impact factor: 6.603

Review 6.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

7.  Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.

Authors:  Abigail J Deloria; Doris Höflmayer; Philip Kienzl; Justyna Łopatecka; Sandra Sampl; Martin Klimpfinger; Tamara Braunschmid; Fabienne Bastian; Lingeng Lu; Brigitte Marian; Stefan Stättner; Klaus Holzmann
Journal:  Oncotarget       Date:  2016-11-08

8.  Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells.

Authors:  Ziyi Yu; Longquan Lou; Yi Zhao
Journal:  Oncol Rep       Date:  2018-06-07       Impact factor: 3.906

9.  Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.

Authors:  Gerd Jomrich; Xenia Hudec; Felix Harpain; Daniel Winkler; Gerald Timelthaler; Thomas Mohr; Brigitte Marian; Sebastian F Schoppmann
Journal:  Cells       Date:  2019-09-16       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.